Clinical Cancer Research Development

Slamon, Dennis J.

Abstract

Funding Agency

• Agency: National Institute of Health (NIH)
• Institute: National Cancer Institute (NCI)
• Type: Physician Scientist Award (Program) (PSA) (K12)
• Project #: 5K12CA001714-05
• Application #: 2084350
• Study Section: Special Emphasis Panel (SRC (72))
• Project Start: 1992-09-30
• Project End: 1997-08-31
• Budget Start: 1996-09-01
• Budget End: 1997-08-31
• Support Year: 5
• Fiscal Year: 1996

Institution

• Name: University of California Los Angeles
• Department: Internal Medicine/Medicine
• Type: Schools of Medicine
• DUNS #: 119132785
• City: Los Angeles
• State: CA
• Country: United States
• Zip Code: 90095

Publications

Pegram, M D; Lipton, A; Hayes, D F et al. (1998) Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. J Clin Oncol 16:2659-71

Landgraf, R; Pegram, M; Slamon, D J et al. (1998) Cytotoxicity and specificity of directed toxins composed of diphtheria toxin and the EGF-like domain of heregulin beta1. Biochemistry 37:3220-8

Pegram, M D; Finn, R S; Arzoo, K et al. (1997) The effect of HER-2/neu overexpression on chemotherapeutic drug sensitivity in human breast and ovarian cancer cells. Oncogene 15:537-47

MacGrogan, D; Pegram, M; Slamon, D et al. (1997) Comparative mutational analysis of DPC4 (Smad4) in prostatic and colorectal carcinomas. Oncogene 15:1111-4

Reese, D M; Slamon, D J (1997) HER-2/neu signal transduction in human breast and ovarian cancer. Stem Cells 15:1-8

Pietras, R J; Fendly, B M; Chazin, V R et al. (1994) Antibody to HER-2/neu receptor blocks DNA repair after cisplatin in human breast and ovarian cancer cells. Oncogene 9:1829-38